PF-06821497 Tratamento de câncer de próstata recidivado/refratário, câncer de próstata resistente à castração e linfoma folicular
UM ESCALAMENTO DE DOSE DE FASE I E ESTUDO DE COORTE EXPANDIDO DE PF-06821497 NO TRATAMENTO DE PACIENTES ADULTOS COM CÂNCER DE PULMÃO DE PEQUENAS CÉLULAS RECIDIVADA/REFRATÁRIA (CPPC), CÂNCER DE PRÓSTATA RESISTENTE À CASTRAÇÃO (CRPC) E LINFOMA FOLICULAR (FL)
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.
Part 3, which is open for enrollment is seeking men who:
- have Castration Resistant Prostate Cancer (CRPC) and
- have previously received treatment for CRPC and have progressed from the last treatment
All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).
In the assessment phase:
- participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
- participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
- participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.
After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.
The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).
Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Pfizer CT.gov Call Center
- Número de telefone: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Locais de estudo
-
-
-
Haskovo, Bulgária, 6300
- Rescindido
- Specialized Hospital for Active Treatment of Oncology - Haskovo
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Ativo, não recrutando
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Ativo, não recrutando
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Ativo, não recrutando
- Zhongda Hospital Southeast University
-
Nanjing, Jiangsu, China, 210008
- Ativo, não recrutando
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recrutamento
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- Ativo, não recrutando
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Coréia do Sul, 13620
- Recrutamento
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [seoul]
-
Seoul, Seoul-teukbyeolsi [seoul], Coréia do Sul, 03080
- Ativo, não recrutando
- Seoul National University Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Coréia do Sul, 07985
- Ativo, não recrutando
- Ewha Womans University Mokdong Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Coréia do Sul, 03722
- Ativo, não recrutando
- Severance Hospital, Yonsei University Health System
-
-
Taejǒn-kwangyǒkshi
-
Daejeon, Taejǒn-kwangyǒkshi, Coréia do Sul, 35015
- Ativo, não recrutando
- Chungnam national university hospital
-
-
-
-
-
Barcelona, Espanha, 08035
- Recrutamento
- Hospital Universitari Vall d'Hebron
-
Barcelona, Espanha, 08036
- Recrutamento
- Hospital Clinic de Barcelona
-
Barcelona, Espanha, 08023
- Recrutamento
- Hospital Quironsalud Barcelona
-
Madrid, Espanha, 28034
- Recrutamento
- Hospital Universitario Ramon y Cajal
-
Madrid, Espanha, 28050
- Recrutamento
- Hospital Universitario HM Sanchinarro
-
Madrid, Espanha, 28040
- Recrutamento
- H.U. Fundación Jiménez Díaz
-
Madrid, Espanha, 28041
- Recrutamento
- Hospital Universitario 12 De Octubre
-
Málaga, Espanha, 29010
- Recrutamento
- Hospital Universitario Virgen de la Victoria
-
Valencia, Espanha, 46026
- Ativo, não recrutando
- Hospital Universitari i Politecnic La Fe
-
-
Barecelona
-
L'Hospitalet de Llobregat, Barecelona, Espanha, 08908
- Ativo, não recrutando
- Institut Català d´Oncología (ICO)-H. Durán i Reynals
-
-
Castellon
-
Castellon, Castellon, Espanha, 12002
- Ativo, não recrutando
- Consorcio Hospitalario Provincial de Castellon
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Espanha, 28223
- Recrutamento
- Hospital Quironsalud Madrid
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Espanha, 28040
- Recrutamento
- Hospital Clinico San Carlos
-
-
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85719
- Ativo, não recrutando
- Banner-University Medical Center Tucson
-
Tucson, Arizona, Estados Unidos, 85719
- Ativo, não recrutando
- The University of Arizona Cancer Center-North Campus
-
Tucson, Arizona, Estados Unidos, 85724
- Ativo, não recrutando
- The University of Arizona Cancer Center
-
Tucson, Arizona, Estados Unidos, 85741
- Rescindido
- Arizona Urology Specialists, PLLC
-
-
California
-
Anaheim, California, Estados Unidos, 92801
- Ativo, não recrutando
- Pacific Cancer Medical Center INC
-
Duarte, California, Estados Unidos, 91010
- Ativo, não recrutando
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Duarte, California, Estados Unidos, 91010
- Ativo, não recrutando
- City of Hope Investigational Drug Services (IDS)
-
-
Connecticut
-
Norwalk, Connecticut, Estados Unidos, 06856
- Ativo, não recrutando
- Norwalk Hospital
-
-
Kansas
-
Fairway, Kansas, Estados Unidos, 66205
- Ativo, não recrutando
- The University of Kansas Cancer Center, Investigational Drug Services
-
Fairway, Kansas, Estados Unidos, 66205
- Ativo, não recrutando
- The University of Kansas Clinical Research Center
-
Kansas City, Kansas, Estados Unidos, 66160
- Ativo, não recrutando
- The University of Kansas Hospital
-
Kansas City, Kansas, Estados Unidos, 66160
- Ativo, não recrutando
- The University of Kansas Medical Center Medical Office Building
-
Overland Park, Kansas, Estados Unidos, 66211
- Ativo, não recrutando
- The University of Kansas Cancer Center - Indian Creek Campus
-
Westwood, Kansas, Estados Unidos, 66205
- Ativo, não recrutando
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Ativo, não recrutando
- Norton Cancer Institute, Norton Healthcare Pavilion
-
Louisville, Kentucky, Estados Unidos, 40202
- Ativo, não recrutando
- Norton Hospital
-
Louisville, Kentucky, Estados Unidos, 40202
- Ativo, não recrutando
- Norton Cancer Institute - Downtown
-
-
Maryland
-
Rockville, Maryland, Estados Unidos, 20850
- Rescindido
- Maryland Oncology Hematology, P.A.
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Ativo, não recrutando
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Estados Unidos, 02115
- Ativo, não recrutando
- Brigham and Women's Hospital
-
Newton, Massachusetts, Estados Unidos, 02459
- Ativo, não recrutando
- Dana Farber Cancer Institute- Chestnut Hill
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130
- Recrutamento
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Ativo, não recrutando
- Hackensack University Medical Center
-
Hackensack, New Jersey, Estados Unidos, 07601
- Ativo, não recrutando
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Recrutamento
- OU Health University of Oklahoma Medical Center
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Recrutamento
- Stephenson Cancer Center (chemo location)
-
-
South Carolina
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Recrutamento
- Carolina Urologic Research Center
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Recrutamento
- Parkway Surgery Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Recrutamento
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Estados Unidos, 37203
- Recrutamento
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- Rescindido
- Texas Oncology - Austin Midtown
-
Dallas, Texas, Estados Unidos, 75390
- Ativo, não recrutando
- UT Southwestern Medical Center
-
Dallas, Texas, Estados Unidos, 75390
- Ativo, não recrutando
- University of Texas Southwestern Medical Center - Simmons Cancer Center
-
Dallas, Texas, Estados Unidos, 75390
- Ativo, não recrutando
- UT Southwestern University Hospital - William P. Clements, Jr
-
Dallas, Texas, Estados Unidos, 75390
- Ativo, não recrutando
- UT Southwestern University Hospital - Zale Lipshy
-
Irving, Texas, Estados Unidos, 75063
- Rescindido
- US Oncology Investigational Product Center (IPC)
-
Irving, Texas, Estados Unidos, 75063
- Rescindido
- US Oncology Investigational Products Center
-
Irving, Texas, Estados Unidos, 75039
- Recrutamento
- NEXT Dallas
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- NEXT Oncology
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Ativo, não recrutando
- Virginia Cancer Specialists, PC
-
-
Washington
-
Port Angeles, Washington, Estados Unidos, 98362
- Ativo, não recrutando
- Olympic Medical Center
-
Poulsbo, Washington, Estados Unidos, 98370
- Ativo, não recrutando
- Fred Hutchinson Cancer Center Alliance Peninsula
-
Seattle, Washington, Estados Unidos, 98195
- Ativo, não recrutando
- University of Washington Medical Center
-
Seattle, Washington, Estados Unidos, 98109
- Ativo, não recrutando
- Fred Hutchinson Cancer Center
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japão, 277-8577
- Ativo, não recrutando
- National Cancer Center Hospital East
-
-
-
-
-
Bydgoszcz, Polônia, 85-048
- Ainda não está recrutando
- In-Vivo Sp. z o.o. In-vivo Bydgoszcz
-
Koszalin, Polônia, 75-581
- Ativo, não recrutando
- Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
-
Krakow, Polônia, 30-348
- Recrutamento
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
-
Rzeszów, Polônia, 35-326
- Ativo, não recrutando
- Centrum Medyczne MEDYK
-
Warsaw, Polônia, 02-781
- Ativo, não recrutando
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
-
-
-
-
-
Moscow, Rússia, 117186
- Ativo, não recrutando
- LLC "Neyro-klinika"
-
Moscow, Rússia, 125284
- Rescindido
- Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
-
Moscow, Rússia, 129301
- Rescindido
- SBHI of Moscow City Clinical Hospital
-
Omsk, Rússia, 644013
- Rescindido
- Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
-
Saint Petersburg, Rússia, 197341
- Rescindido
- Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
-
Saint Petersburg, Rússia, 197758
- Rescindido
- Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
-
Saint Petersburg, Rússia, 198255
- Rescindido
- Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
-
Yaroslavl, Rússia, 150054
- Rescindido
- State Budgetary Healthcare Institution of the Yaroslavl Region
-
-
Sankt-Peterburg
-
Pushkin, Sankt-Peterburg, Rússia, 196603
- Ativo, não recrutando
- Private Medical Institution "Euromedservice"
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Part 1 and Part 2 (Closed for enrollment).
Part 3 Key Inclusion Criteria:
- Histological or cytological diagnosis of castration resistant prostate cancer.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
- Adequate bone marrow, renal, and liver function
Part 3 Key Exclusion Criteria:
- Prior irradiation to >25% of the bone marrow.
- QTcF interval >480 msec at screening.
- Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
- Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
- Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
- Prior enzalutamide within the last 4 weeks
- DDI SUBSTUDY:
- history of CHF or evidence of ventricular dysfunction
- fructose intolerance
- coadministration of CYP3A4 substrates
- Any history of prior malignancies, except for carcinoma in situ or non-melanoma skin cancer, prior non-hematologic malignancies >= 3 years before randomization with no subsequent recurrence or progression, Stage 0 or 1 non-hematologic cancer < 3 years before randomization that has a remote probability of recurrence or progression.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Dose Escalation (Part 1A)
Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels |
Oral continuous
Outros nomes:
|
|
Experimental: Dose Escalation (Part 1B)
Participants with FL will receive mevrometostat at escalating dose levels |
Oral continuous
Outros nomes:
|
|
Experimental: Dose Escalation (Part 1C)
Participants with mCRPC will receive mevrometostat at escalating dose levels. |
Oral continuous
Outros nomes:
|
|
Experimental: Dose Escalation (Part 2A)
Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC. |
Oral continuous
Outros nomes:
Oral continuous
Outros nomes:
|
|
Experimental: Dose Expansion (Part 2B)
Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone. |
Oral continuous
Outros nomes:
Oral continuous
Outros nomes:
|
|
Experimental: Japan Cohort
Participants with CRPC will receive mevrometostat at one or two doses |
Oral continuous
Outros nomes:
|
|
Experimental: China cohort
Participants will receive mevrometostat at one or two doses |
Oral continuous
Outros nomes:
|
|
Experimental: Dose Expansion (Part 2C)
Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC |
Oral continuous
Outros nomes:
Oral continuous
Outros nomes:
|
|
Experimental: BE Substudy
In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Outros nomes:
Oral continuous
Outros nomes:
|
|
Experimental: DDI Substudy
The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Outros nomes:
Oral continuous
Outros nomes:
Oral solution
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Prazo: Baseline up to 90 days
|
First cycle DLTs will be utilized to determine the MTD |
Baseline up to 90 days
|
|
Overall safety profile including adverse events
Prazo: Baseline up to approximately 2 years
|
Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03]) |
Baseline up to approximately 2 years
|
|
Preliminary efficacy determination as evaluated by disease specific response criteria
Prazo: Through study completion, approximately 2 years past last patient first visit.
|
Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC. |
Through study completion, approximately 2 years past last patient first visit.
|
|
Overall safety profile including laboratory abnormalities
Prazo: Baseline up to approximately 2 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing. |
Baseline up to approximately 2 years
|
|
Overall safety profile including vital signs
Prazo: Baseline up to approximately 2 years
|
Vital sign changes from baseline including blood pressure, heart rate, ECG changes. |
Baseline up to approximately 2 years
|
|
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Prazo: Baseline until disease progression or death or through study completion (approx 2 years)
|
PCWG3 |
Baseline until disease progression or death or through study completion (approx 2 years)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Prazo: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC) |
Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
|
Evaluate overall survival
Prazo: Baseline up to approximately 2 years
|
Median time to death proportion of patients alive at 6 months, 1 year, and 2 years. |
Baseline up to approximately 2 years
|
|
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Prazo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Prazo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Prazo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Prazo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Prazo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Prazo: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Singe dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Evaluate the impact of mevrometostat on patient reported outcomes.
Prazo: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P. |
At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
|
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Prazo: At specific time points from Cycle1 Day 1 to end of treatment
|
Questionnaire customized from PRO-CTCAE. |
At specific time points from Cycle1 Day 1 to end of treatment
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Diretor de estudo: Pfizer CT.gov Call Center, Pfizer
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Neoplasias por local
- Neoplasias
- Atributos da doença
- Doenças do sistema imunológico
- Doenças Respiratórias
- Neoplasias por Tipo Histológico
- Doenças pulmonares
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Neoplasias Pulmonares
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Linfoma Não-Hodgkin
- Linfoma
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Condições Patológicas, Sinais e Sintomas
- Doenças hemic e linfáticas
- Recorrência
- Carcinoma pulmonar de pequenas células
- Linfoma Folicular
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Azoles
- Triazóis
- Piperazinas
- Itraconazol
- enzalutamida
- PF06821497
Outros números de identificação do estudo
Outros números de identificação do estudo
- C2321001
- 2023-509179-18-00 (Identificador de registro: CTIS (EU))
- EZH2 (Outro identificador: Alias Study Number)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .